Ethics Committees of two major clinics (in Moscow and St.Petersburg) approved NucleoCapture to proceed with a clinical trial first in human clinical trials in sepsis/SAKI patients. The aim of the trial is to evaluate the safety of the device as well as the efficacy in removing cfDNA/NETs in patients with SAKI or with high risk of SAKI.
“We are very optimistic and excited to be a part of a revolutionary way of treating this unmet clinical need. We are obviously confident due to the success of our pre-clinical large animal studies however are very aware of the pitfalls moving into first in human trials. This is a historic moment for Santersus AG and we will stride forward to quickly and efficiently disrupt the current therapeutic modalities”.